vs
CytomX Therapeutics, Inc.（CTMX）与PLUMAS BANCORP（PLBC）财务数据对比。点击上方公司名可切换其他公司
PLUMAS BANCORP的季度营收约是CytomX Therapeutics, Inc.的1.5倍（$28.6M vs $18.7M），PLUMAS BANCORP同比增速更快（35.1% vs -25.7%），PLUMAS BANCORP自由现金流更多（$20.3M vs $-15.8M），过去两年PLUMAS BANCORP的营收复合增速更高（20.8% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
Plumas Bancorp是一家美国银行控股公司，通过旗下子公司Plumas Bank开展业务，为加利福尼亚州北部及内华达州的个人客户、中小企业和本地社区机构提供存款、各类贷款、财富管理等综合零售及商业银行服务。
CTMX vs PLBC — 直观对比
营收规模更大
PLBC
是对方的1.5倍
$18.7M
营收增速更快
PLBC
高出60.8%
-25.7%
自由现金流更多
PLBC
多$36.1M
$-15.8M
两年增速更快
PLBC
近两年复合增速
-15.9%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $28.6M |
| 净利润 | $-154.0K | — |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | 48.9% |
| 净利率 | -0.8% | — |
| 营收同比 | -25.7% | 35.1% |
| 净利润同比 | 97.6% | — |
| 每股收益（稀释后） | — | $1.56 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXPLBC
| Q4 25 | — | $28.6M | ||
| Q3 25 | — | $27.4M | ||
| Q2 25 | $18.7M | $20.5M | ||
| Q1 25 | $50.9M | $21.8M | ||
| Q4 24 | $38.1M | $21.2M | ||
| Q3 24 | $33.4M | $21.1M | ||
| Q2 24 | $25.1M | $20.6M | ||
| Q1 24 | $41.5M | $19.6M |
净利润CTMXPLBC
| Q4 25 | — | — | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | $-154.0K | $6.3M | ||
| Q1 25 | $23.5M | $7.2M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $7.8M | ||
| Q2 24 | $-6.5M | $6.8M | ||
| Q1 24 | $13.8M | $6.3M |
营业利润率CTMXPLBC
| Q4 25 | — | 48.9% | ||
| Q3 25 | — | 25.2% | ||
| Q2 25 | -6.9% | 42.2% | ||
| Q1 25 | 44.4% | 46.1% | ||
| Q4 24 | 46.4% | 50.3% | ||
| Q3 24 | 12.3% | 50.6% | ||
| Q2 24 | -33.7% | 45.1% | ||
| Q1 24 | 28.1% | 42.8% |
净利率CTMXPLBC
| Q4 25 | — | — | ||
| Q3 25 | — | 18.8% | ||
| Q2 25 | -0.8% | 30.8% | ||
| Q1 25 | 46.2% | 33.0% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | 37.1% | ||
| Q2 24 | -26.0% | 32.9% | ||
| Q1 24 | 33.3% | 31.9% |
每股收益（稀释后）CTMXPLBC
| Q4 25 | — | $1.56 | ||
| Q3 25 | — | $0.73 | ||
| Q2 25 | — | $1.05 | ||
| Q1 25 | — | $1.20 | ||
| Q4 24 | — | $1.30 | ||
| Q3 24 | — | $1.31 | ||
| Q2 24 | — | $1.14 | ||
| Q1 24 | — | $1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $80.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $261.1M |
| 总资产 | $175.1M | $2.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXPLBC
| Q4 25 | — | $80.6M | ||
| Q3 25 | — | $87.3M | ||
| Q2 25 | $49.0M | $79.3M | ||
| Q1 25 | $47.6M | $87.3M | ||
| Q4 24 | $38.1M | $82.0M | ||
| Q3 24 | $40.6M | $118.0M | ||
| Q2 24 | $43.2M | $109.9M | ||
| Q1 24 | $36.2M | $128.2M |
股东权益CTMXPLBC
| Q4 25 | — | $261.1M | ||
| Q3 25 | — | $245.9M | ||
| Q2 25 | $119.9M | $193.1M | ||
| Q1 25 | $25.0M | $187.6M | ||
| Q4 24 | $-456.0K | $177.9M | ||
| Q3 24 | $-23.5M | $181.9M | ||
| Q2 24 | $-31.2M | $165.2M | ||
| Q1 24 | $-31.7M | $161.5M |
总资产CTMXPLBC
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | $175.1M | $1.6B | ||
| Q1 25 | $98.5M | $1.6B | ||
| Q4 24 | $120.5M | $1.6B | ||
| Q3 24 | $139.0M | $1.7B | ||
| Q2 24 | $159.2M | $1.6B | ||
| Q1 24 | $184.7M | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $21.6M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $20.3M |
| 自由现金流率自由现金流/营收 | -84.6% | 70.9% |
| 资本支出强度资本支出/营收 | 0.1% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $34.4M |
8季度趋势，按日历期对齐
经营现金流CTMXPLBC
| Q4 25 | — | $21.6M | ||
| Q3 25 | — | $5.6M | ||
| Q2 25 | $-15.8M | $2.1M | ||
| Q1 25 | $-21.0M | $7.5M | ||
| Q4 24 | $-19.9M | $30.5M | ||
| Q3 24 | $-20.7M | $8.0M | ||
| Q2 24 | $-19.5M | $5.1M | ||
| Q1 24 | $-26.0M | $9.2M |
自由现金流CTMXPLBC
| Q4 25 | — | $20.3M | ||
| Q3 25 | — | $4.8M | ||
| Q2 25 | $-15.8M | $2.0M | ||
| Q1 25 | $-21.2M | $7.3M | ||
| Q4 24 | $-20.0M | $29.8M | ||
| Q3 24 | $-20.7M | $7.8M | ||
| Q2 24 | $-19.6M | $4.8M | ||
| Q1 24 | $-26.2M | $9.0M |
自由现金流率CTMXPLBC
| Q4 25 | — | 70.9% | ||
| Q3 25 | — | 17.5% | ||
| Q2 25 | -84.6% | 9.9% | ||
| Q1 25 | -41.6% | 33.7% | ||
| Q4 24 | -52.5% | 141.0% | ||
| Q3 24 | -62.1% | 37.1% | ||
| Q2 24 | -78.2% | 23.5% | ||
| Q1 24 | -63.1% | 45.8% |
资本支出强度CTMXPLBC
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.2% | 0.8% | ||
| Q4 24 | 0.2% | 3.2% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | 0.4% | 1.1% | ||
| Q1 24 | 0.3% | 1.0% |
现金转化率CTMXPLBC
| Q4 25 | — | — | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 0.33× | ||
| Q1 25 | -0.89× | 1.04× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | 1.02× | ||
| Q2 24 | — | 0.75× | ||
| Q1 24 | -1.89× | 1.46× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
PLBC
暂无分部数据
